Market Place
Sourcing Support
Senhwa Biosciences Appoints Dr. Yiu-Lian Fong as New Director
01 Nov 2024 //
PR NEWSWIRE
US FDA Issues Study May Proceed Letter For Pidnarulex
14 Oct 2024 //
PR NEWSWIRE
Senhwa Submits IND For Pidnarulex Study In Advanced Solid Tumors To US FDA
17 Sep 2024 //
PR NEWSWIRE
FDA Grants RPD Designation To Senhwa`s Silmitasertib For Neuroblastoma
12 Sep 2024 //
PR NEWSWIRE
Senhwa Presents Pidnarulex Clinical Data At ESMO 2024
08 Sep 2024 //
PR NEWSWIRE
Senhwa Biosciences Announces Jason Huang, MD as New Chief Medical Officer
13 May 2024 //
PR NEWSWIRE
AACR 2024 Annual Meeting-Visit Senhwa Biosciences Exhibit Booth
03 Apr 2024 //
PR NEWSWIRE
Senhwa Announces First Patient Dosed in the Phase II of Silmitasertib
20 Mar 2024 //
PR NEWSWIRE
Senhwa Bio Received US FDA IND Approval for Phase II Study of Silmitasertib
21 Nov 2023 //
PR NEWSWIRE
Senhwa Announces First Patient Dosed in Taiwan Phase II Study of Silmitasertib
09 Nov 2023 //
PR NEWSWIRE
Senhwa Announces IND Submission to US FDA for Phase II Study of Silmitasertib
19 Oct 2023 //
PR NEWSWIRE
Taiwan FDA approves Senhwa Biosciences’ ph II IND application of Silmitasertib
02 May 2023 //
PHARMABIZ
Senhwa Bio Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib
28 Apr 2023 //
PR NEWSWIRE
Senhwa Announces Successful Awardee of Anticancer Pipeline in NExT Program
01 Dec 2022 //
PRNEWSWIRE
Senhwa Announces First Patient Dosed in PI Study of Pindnarulex with Talazoparib
31 Oct 2022 //
PRNEWSWIRE
Senhwa`s Pindnarulex in Combo with Pfizer`s Talazoparib for Prostate Cancer
06 Jun 2022 //
PRNEWSWIRE
Senhwa Presents Positive Initial Data from Trial of Silmitasertib at AAD
28 Mar 2022 //
PRNEWSWIRE
Senhwa`s Pidnarulex Receives US FDA FTD for Solid Tumors with BRCA1/2, PALB2
25 Jan 2022 //
PRNEWSWIRE
Senhwa`s Silmitasertib Receives US FDA ODD for Biliary Tract Cancer
20 Jan 2022 //
PRNEWSWIRE
Senhwa`s Silmitasertib Receives FDA ODD in Medulloblastoma
17 Dec 2021 //
PRNEWSWIRE
Senhwa Clinical Data Abstract for Silmitasertib in BCC Accepted for 2022 AAD
16 Dec 2021 //
PRNEWSWIRE
Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO
26 Nov 2021 //
SENHWABIO
Senhwa Announces Abstract Accepted for Presentation at the 2022 ASCO
15 Nov 2021 //
PRNEWSWIRE
Senhwa reports positive data from Phase II trial of Covid-19 therapy
21 Oct 2021 //
CLINICALTRIALSARENA
Senhwa Presents Positive Initial Data from Ph2 Trial of Silmitasertib (CX-4945)
20 Oct 2021 //
PRNEWSWIRE
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study
27 Sep 2021 //
PRNEWSWIRE
Senhwa initiates dosing in PIb expansion study of Pidnarulex in solid tumors
13 Sep 2021 //
PHARMABIZ
Senhwa`s First Patient Dosed in Phase 1b Expansion Study of Pidnarulex
10 Sep 2021 //
BIOSPACE
Senhwa`s Silmitasertib Receives Positive Review from Data Monitoring Committee
31 Aug 2021 //
PRNEWSWIRE
Senhwa Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex
25 Aug 2021 //
PRNEWSWIRE
Senhwa`s Silmitasertib Receives US FDA Fast Track Designation
18 Aug 2021 //
PRNEWSWIRE
Senhwa completes enrollment in phase 2 trial of Silmitasertib to treat Covid-19.
17 Aug 2021 //
PHARMABIZ
Senhwa Completes Enrollment of Phase 2 Trial of Silmitasertib
16 Aug 2021 //
PR NEWSWIRE
Senhwa concludes enrolment in Phase II oral Covid-19 drug trial
16 Aug 2021 //
CLINICALTRIALSARENA
Taiwan`s Centre for Drug Evaluation initiates new drug trial against COVID-19
16 Aug 2021 //
BIOSPECTRUMASIA
Arctic Vision Expands License for ARVN001 to Include ASEAN Countries and India
15 Aug 2021 //
PR NEWSWIRE
Senhwa Signs Agreement with Taiwan`s CDE for COVID-19 Program of Silmitasertib
13 Aug 2021 //
PR NEWSWIRE
Senhwa seeks India’s CDSCO approval for Phase II Covid-19 drug trial
24 Jun 2021 //
CLINICAL TRAILS ARENA
Kimshealth Thiruvananthapuram hospital invests Rs 300 crore to set up new hosP
23 Jan 2021 //
PHARMABIZ
Senhwa begins patient dosing in phase II trial of Silmitasertib
22 Jan 2021 //
PHARMABIZ
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial
22 Jan 2021 //
PRESS RELEASE
Senhwa Announces the First Patient Enrolled in an Investigator Initiated
21 Jan 2021 //
PRNEWSWIRE
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial
21 Jan 2021 //
PRNEWSWIRE
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data
15 Jan 2021 //
PRNASIA
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data
15 Jan 2021 //
BIOSPACE
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data
15 Jan 2021 //
PRESS RELEASE
Senhwa Biosciences Receives US FDA `Study May Proceed` Letter to Treat BRCA2
23 Dec 2020 //
PRNEWSWIRE
Senhwa Biosciences Receives US FDA `Study May Proceed` Letter to Treat BRCA2
23 Dec 2020 //
PRNASIA
Senhwa Biosciences Receives US FDA `Study May Proceed` Letter to Treat CX-5461
23 Dec 2020 //
PRNEWSWIRE
Senhwa Biosciences Receives US FDA `Study May Proceed` Letter to Treat BRCA2+
23 Dec 2020 //
PRNASIA
Senhwa Biosciences`s Positive Topline Cholangiocarcinoma Data
14 Dec 2020 //
PRNEWSWIRE
Senhwa Biosciences enrols first patient in Covid-19 investigational drug trial
04 Dec 2020 //
CLINICALTRIALSARENA
Senhwa Announces the First Patient Enrolled in Initiated Trial Of Silmitasertib
03 Dec 2020 //
PRNEWSWIRE
Senhwa Announces Multiple IND Application Submissions to US FDA
26 Nov 2020 //
PRNASIA
Senhwa Announces Multiple IND Application Sub to US FDA and Health Canada
25 Nov 2020 //
PRNEWSWIRE
Senhwa Announces Multiple IND Application Submissions to US FDA
25 Nov 2020 //
PRNASIA
CARE GA Receives Study May Proceed Letter from US FDA to Initiate PhII Trial
06 Nov 2020 //
PRNASIA
Senhwa Announces Multiple IND app submissions to U.S. FDA for Silmitasertib
02 Nov 2020 //
PRNEWSWIRE
Senhwa Announces Multiple IND app submissions to U.S. FDA for Silmitasertib
02 Nov 2020 //
PRNASIA
Taiwan reports first COVID-19 patient recovery with eIND Silmitasertib treatment
15 Sep 2020 //
BIOSPECTRUM ASIA
